Appropriate timing of proton MR spectroscopy in breast cancer

Magnetic Resonance in Medical Sciences

Volumn 10, Issue 2, 2011, Pages 71-77

  Tozaki, Mitsuhiro ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Proton MRS; Therapeutic response

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST TUMOR; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; REVIEW; TIME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855745727     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.10.71     Document Type: Review

References (27)

1. Lean C, Doran S, Somorjai RL, et al. Determination of grade and receptor status from the primary breast lesion by magnetic resonance spectroscopy. Technol Cancer Res Treat 2004; 3:551-556.
2. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histological prognostic factors. AJR Am J Roentgenol 2010; 194:1384-1390.
3. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001; 84:1016-1022.
4. 1H MR spectroscopy-a pilot study at 4T. Radiology 2004; 233:424-431.
5. Kumar M, Jagannathan NR, Seenu V, Dwivedi SN, Julka PK, Rath GK. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectros-copy study. J Magn Reson Imaging 2006; 24:325- 332.
6. Manton DJ, Chaturvedi A, Hubbard A, et al. Ne-oadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006; 94:427-435.
7. 1H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008; 28:420-427.
8. 1H MR spectroscopy. Radiology 2009; 251:653-662.
9. Tozaki M. What is best for early response to chemotherapy: size, curve, diffusion, spectroscopy, PET? Eur Radiol 2009; 19:S944-946.
10. 1H MR spectroscopy with diffusion MR imaging. Jpn J Radiol 2010; 28:101-109.
11. 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 2010; 31:895-902.
12. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluoro-deoxyglucose positron emission tomography. J Clin Oncol 2006; 24:5366-5372.
13. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998; 209: 269-275.
14. 1H MR spectroscopy. J Magn Reson Imaging 1999; 10:159-164.
15. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001; 68:45-54.
16. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology 2001; 220:40-46.
17. Tse GM, Cheung HS, Pang LM, et al. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benignlesions, and phyllodes tumors. AJR Am J Roentgenol 2003; 181:1267-1272.
18. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004; 232:585-591.
19. Bartella L, Morris EA, Dershaw DD, et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006; 239:686-692.
20. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vor-buchner M, Podo F. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol 2009; 192:1608-1617.
21. Tozaki M, Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy? AJR Am J Roentgenol 2009; 193:840-849.
22. ®-MRI, In: ACR Breast imaging reporting and data system, Reston, VA: American College of Radiology, 2003.
23. Sakamoto M, Tozaki M, Sagawa N, Kawano N, Fukuma E, Hoshi K. [A case of angiosarcoma of the breast.] J Jpn Surg Assoc 2009; 70:2633-2636. [Japanese with English abstract]
24. Tozaki M, Maruyama K. Current status and future prospects of proton MR spectroscopy of the breast with a 1.5T MR unit. J Oncol 2010; 2010. pii: 781621. Epub 2010 Sep 26.
25. Bartella L, Thakur SB, Morris EA, et al. Enhancing nonmass lesions in the breast: evaluation with proton 1H MR spectroscopy. Radiology 2007; 245:80-87.
26. Tozaki M, Igarashi T, Fukuda K. Breast MRI using the VIBE sequence: clustered ring enhancement in the differential diagnosis of lesions showing non-masslike enhancement. AJR Am J Roentgenol 2006; 187:313-321.
27. Tozaki M, Fukuda K. High-spatial-resolution MRI of non-masslike breast lesions: interpretation model based on BI-RADS MRI descriptors. AJR Am J Roentgenol 2006; 187:330-337.